Published in Cochrane Database Syst Rev on July 16, 2008
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2010) 1.58
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev (2010) 1.52
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev (2009) 1.33
Management of acute asthma in adults in the emergency department: nonventilatory management. CMAJ (2009) 1.24
Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev (2009) 1.14
Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev (2012) 1.11
Pharmacogenetics of asthma. Curr Opin Pulm Med (2009) 0.99
Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2012) 0.98
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol (2015) 0.97
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev (2010) 0.92
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.92
Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. BMJ (2015) 0.85
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.85
Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality. CMAJ (2013) 0.80
Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments. Mol Pharm (2016) 0.78
Long-acting beta-agonists and the risk of intensive care unit admission in children. J Asthma (2012) 0.77
Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update. Br J Pharmacol (2016) 0.77
Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones. Pharmacol Ther (2016) 0.75
Asthma and other recurrent wheezing disorders in children (chronic). BMJ Clin Evid (2012) 0.75
Asthma in adults. BMJ Clin Evid (2011) 0.75
Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma. Evid Based Med (2009) 0.75
Optimization of substituted imidazobenzodiazepines as novel asthma treatments. Eur J Med Chem (2016) 0.75
Salmeterol use and risk of hospitalization among emergency department patients with acute asthma. Ann Allergy Asthma Immunol (2010) 0.75
Long-Acting Beta Agonists Enhance Allergic Airway Disease. PLoS One (2015) 0.75
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2012) 0.75
Should salmeterol be used for long-term asthma control? Am Fam Physician (2009) 0.75
Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes. Patient Relat Outcome Meas (2011) 0.75
The impact of Cochrane Systematic Reviews: a mixed method evaluation of outputs from Cochrane Review Groups supported by the UK National Institute for Health Research. Syst Rev (2014) 0.75
Observations on recent increase in mortality from asthma. Br Med J (1968) 14.82
Interaction revisited: the difference between two estimates. BMJ (2003) 11.97
Regular inhaled beta-agonist treatment in bronchial asthma. Lancet (1990) 9.93
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
Eosinophilic inflammation in asthma. N Engl J Med (1990) 8.05
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med (2006) 7.83
Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med (2000) 5.82
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet (1989) 5.82
The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol (1960) 5.41
Bronchial hyperreactivity. Am Rev Respir Dis (1980) 4.77
Regular inhaled salbutamol and airway responsiveness to allergen. Lancet (1993) 4.43
Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet (1981) 4.28
Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br J Pharmacol (1969) 3.86
Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis (1972) 3.77
Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax (1991) 3.39
Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med (1983) 3.27
Characterization of airway plugging in fatal asthma. Am J Med (2003) 3.23
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 3.21
A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med (1997) 3.19
Role of autonomic nervous system and the cough reflex in the increased responsiveness of airways in patients with obstructive airway disease. J Clin Invest (1967) 3.09
Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA (1994) 3.03
Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax (1990) 3.02
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med (2004) 2.93
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol (2004) 2.80
Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis (1993) 2.69
Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med (2001) 2.53
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med (1992) 2.52
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet (1990) 2.52
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev (2006) 2.30
Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med (2000) 2.30
The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis (1993) 2.23
One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med (1997) 2.16
Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1990) 2.14
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax (2000) 2.10
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med (1992) 2.10
A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. Chest (2000) 2.06
A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest (2001) 2.00
Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med (1995) 1.85
Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart. Circ Res (1989) 1.82
Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax (1982) 1.77
Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax (1998) 1.72
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Misleading data analyses in salmeterol (SMART) study. Lancet (2005) 1.60
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J (1999) 1.58
Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev (2005) 1.56
Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest (1999) 1.51
Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis (1990) 1.50
Case-control study of salmeterol and near-fatal attacks of asthma. Thorax (1998) 1.49
Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database Syst Rev (2002) 1.48
Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med (1999) 1.48
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med (2006) 1.46
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol (1999) 1.46
Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med (1999) 1.45
Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol (1995) 1.43
Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects. Chest (2002) 1.42
Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction. Respir Med (2005) 1.42
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax (2001) 1.41
Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci (1993) 1.39
2 new groups of selective stimulants of adrenergic beta-receptors. Experientia (1969) 1.36
Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Saf (1997) 1.35
Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J (1996) 1.33
HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis. Am Rev Respir Dis (1993) 1.26
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. Eur Respir J (1992) 1.24
Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group. Thorax (1993) 1.22
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis (1989) 1.20
Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ (1997) 1.20
Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev (2005) 1.19
Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med (1998) 1.19
Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol (1999) 1.18
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev (2007) 1.17
Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol (2000) 1.14
Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med (1998) 1.12
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax (1998) 1.11
Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med (2000) 1.10
Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol (1995) 1.08
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol (1999) 1.08
Inflammation and airway function in asthma: what you see is not necessarily what you get. Am J Respir Crit Care Med (1998) 1.08
A model of the mechanics of airway narrowing. J Appl Physiol (1985) (1990) 1.07
Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax (2000) 1.06
A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Am Rev Respir Dis (1991) 1.04
Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol (1982) 1.03
Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J (1999) 1.01
Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus. Int Arch Allergy Immunol (2001) 1.01
An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med (1996) 1.01
Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. Respir Med (1995) 1.00
Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther (2008) 1.00
Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med (2002) 0.99
A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children. Respir Med (1998) 0.99
Salmeterol (Serevent) asthma trial halted early. CMAJ (2003) 0.99
Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax (1993) 0.97
Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol (2006) 0.96
A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol (1992) 0.96
Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax (1994) 0.95
Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. J Allergy Clin Immunol (1990) 0.95
Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J (1991) 0.95
Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber. Chest (2000) 0.94
Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2008) 1.57
Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2012) 0.98
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.92
Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2009) 0.91
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.85